RJA
HSTO

Raymond James & Associates’s Histogen Inc. Common Stock HSTO Stock Holding History

Raymond James & Associates’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-859
Closed -$28K – 3923
2020
Q3 		$28K Buy
+859
New +$41.4K ﹤0.01% 3492

Other funds holding HSTO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James & Associates's HSTO Position: Q4 2020 in Review

Raymond James & Associates sold out of Histogen Inc. Common Stock (HSTO) in Q4 2020, closing a stake of 859 shares — an estimated $28K sold.

Raymond James & Associates first reported a position in HSTO in Q3 2020 and held it in 1 quarter. The position peaked at $28K in Q3 2020. 19 funds tracked by Wall St. Rank hold HSTO as of Q4 2020.

  • Raymond James & Associates reported no remaining Histogen Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 859 Histogen Inc. Common Stock shares in Q4 2020, an estimated $28K.
  • Raymond James & Associates first reported a position in Histogen Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Raymond James & Associates's Histogen Inc. Common Stock position peaked at $28K in Q3 2020.
  • 19 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.